How to Challenge a Drug Patent: The Complete Playbook for Generic Entry, IP Destruction, and Market Acceleration
Why Patent Challenges Move Markets A single successful Paragraph IV challenge on a blockbuster drug can redirect $2-5 billion in […]
June 2025
How to Check If a Drug Is Patented: The Complete Intelligence Playbook for Pharma Analysts, IP Teams, and Institutional Investors
I. Drug Patent Status as a Financial Variable, Not a Legal Footnote The Misread Signal Most analysts treat drug patent
Drug Portfolio Management: The Regulatory Playbook That Protects Billions in IP
Pharmaceutical companies collectively lose an estimated $250 billion in annual revenue to patent cliffs, regulatory missteps, and compliance failures that
Drug Portfolio Management: The Regulatory Playbook That Protects Billions in IP Read Post »
Patent Cliff Predatory Playbook: How IP Expiration Creates the Best Drug Stock Opportunities
When a pharmaceutical patent expires, it does not quietly fade. It detonates. Revenue can collapse by 80 to 90 percent
Multi-Market Generic Drug Approvals: The Regulatory Submission Playbook That Cuts 12+ Months Off Your Timeline
Generic drug companies that win in multiple markets simultaneously share one trait: they treat the regulatory submission itself as a
Why the World Looks to Switzerland for Pharmaceutical Excellence
Swiss Pharmaceutical Hegemony: Intellectual Property Architecture and Global R&D Dominance Switzerland controls a disproportionate share of global pharmaceutical value. While
Why the World Looks to Switzerland for Pharmaceutical Excellence Read Post »
Drug Patent Thickets: The Complete Anatomy of Pharmaceutical Evergreening, IP Valuation, and the $400 Billion Exclusivity War
AbbVie built 311 patent applications around a single rheumatoid arthritis antibody and extracted more than $200 billion in cumulative revenue
